Jasur Danier
8 Papers
2 Citations
Jasur Danier is an academic researcher. The author has contributed to research in topics: Randomized controlled trial & Vaccination. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons: A Randomized Clinical Trial.
Ghassan Dbaibo,Arshad Amanullah,Carine Claeys,Allen Izu,Varsha K. Jain,Pope Kosalaraksa,Luis Rivera,Jyoti Soni,Emad Yanni,Khalequ Zaman,Beatriz Acosta,Miguel Ariza,Maria L. Arroba Basanta,Ashish Bavdekar,Alfonso Carmona,Luis Cousin,Jasur Danier,Adolfo Diaz,Javier Díez-Domingo,Ener Cagri Dinleyici,Saul N. Faust,José Garcia-Sicilia,Grace D. Gomez-Go,Maria L. A. Gonzales,Mustafa Hacimustafaoglu,Stephen M. Hughes,Teresa Jackowska,Shashi Kant,Marilla G. Lucero,Josep Mares Bermudez,Federico Martinón-Torres,May Montellano,Roman Prymula,Thanyawee Puthanakit,Renata Ruzkova,Iwona Sadowska-Krawczenko,Henryk Szymański,Angels Ulied,Wayne Woo,Anne Schuind,Bruce L. Innis +40 more
TL;DR: This research presents a novel probabilistic approach that allows us to assess the importance of knowing the carrier and removal status of canine coronavirus as a source of infection for other animals.
34
The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: A randomized trial
Jasur Danier,Anicia Arredondo +1 more
TL;DR: In this paper , the authors evaluated simultaneous versus sequential administration of the adjuvanted recombinant zoster vaccine (RZV) and the 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ≥50 years.
11
Association between hemagglutination inhibition antibody titers and protection against RT-PCR confirmed influenza illness in children 6−35 months of age: statistical evaluation of a correlate of protection
Jasur Danier,Andrea Callegaro,Jyoti Soni,Alfoso Carmona,Pope Kosalaraska,Luis Rivera,Damien Friel,Wenji Pu,Valerie Vantomme,Ghassan Dbaibo,Bruce L. Innis,Anne Schuind,Khalequ Zaman,Jerome Wilson +13 more
TL;DR: The study validated HI antibody titer as a statistical CoP, by demonstrating that HI titer is correlated with clinical protection against RT-PCR–confirmed influenza associated with the corresponding influenza strain and is predictive of VE in children 6–35 months of age.
7
No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial
Abdi Naficy,Adrienne Kuxhausen,P. Pirrotta,Brett Leav,Jacqueline Miller,Kate O Anteyi,Jasur Danier,Thomas Breuer,A. Mwakingwe-Omari +8 more
TL;DR: In this article , a randomized, open-label study, eligible adults aged ≥50 years were randomly assigned (1:1) to receive mRNA-1273 (50µg) booster vaccination and a first dose of recombinant zoster vaccine (RZV1) 2 weeks apart (Seq group) or concomitantly (Coad group).
No immunological interference or safety concerns when adjuvanted recombinant zoster vaccine is coadministered with a COVID-19 mRNA-1273 booster vaccine in adults aged 50 years and older: A randomized trial
Abdi Naficy,Adrienne Kuxhausen,P. Pirrotta,Brett Leav,Kate O Anteyi,Matthew Adams,Jasur Danier,Thomas Breuer,A. Mwakingwe-Omari +8 more
TL;DR: In this paper , a randomized, open-label study, eligible adults aged 50 years were randomly assigned (1:1) to receive mRNA-1273 (50g) booster vaccination and a first dose of recombinant zoster vaccine (RZV1) 2 weeks apart (Seq group) or concomitantly (Coad group).
1